Literature DB >> 15009837

The yield of surveillance endomyocardial biopsies as a screen for cellular rejection in pediatric heart transplant patients.

Daniel S Levi1, Adam S DeConde, Michael C Fishbein, Caron Burch, Juan C Alejos, Glenn T Wetzel.   

Abstract

Endomyocardial biopsy is commonly used to screen for cellular rejection in pediatric heart transplant patients. The yield of EMBs when combined with newly developed immunohistochemical techniques and modern immunosuppression in pediatric heart transplant patients is unknown. After OHT, surveillance biopsies were performed on a routine basis on all pediatric patients. EMBs were also performed on symptomatic OHT patients suspected to have rejection. All positive results (greater than ISHLT grade 1B) were confirmed with immunohistochemical staining. A retrospective review of consecutive EMBs performed in this institution from January 1995 to January 2003 was performed. The echocardiographic results, clinical history and treatment changes at the time of every biopsy were also catalogued. Of the 1093 EMB results from 136 pediatric heart transplant grafts (127 patients, 64 male) reviewed, 825 biopsies were performed on patients managed with tacrolimus and 268 were performed on patients managed with cyclosporine. The patients managed with tacrolimus had an incidence of 0.85% (7/825) for significant rejection (greater than ISHLT grade 1B rejection) vs. an incidence of 4.1% (11/268) for the patients on cyclosporine (p < 0.0005). In the asymptomatic tacrolimus patients, only two screening biopsies (0.26%) manifest significant rejection, and both of these were performed within the first month after transplantation. Of the symptomatic tacrolimus patients, 9.1% (n = 5) had findings on biopsy consistent with significant cellular rejection. There were 25 patients with grade 1B rejection. Twenty-two of these patients were not treated, and all cases of grade 1B rejection resolved without clinical sequelae. For pediatric patients more than 30 days after OHT, EMB has failed to reveal significant episodes of cellular rejection in asymptomatic patients managed with tacrolimus. Copyright 2004 Blackwell Munksgaard

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15009837     DOI: 10.1046/j.1397-3142.2003.00115.x

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  4 in total

1.  Long-term surveillance biopsy: Is it necessary after pediatric heart transplant?

Authors:  David M Peng; Victoria Y Ding; Seth A Hollander; Tigran Khalapyan; John C Dykes; David N Rosenthal; Christopher S Almond; Charlotte Sakarovitch; Manisha Desai; Doff B McElhinney
Journal:  Pediatr Transplant       Date:  2018-12-01

2.  Endomyocardial biopsy and selective coronary angiography are low-risk procedures in pediatric heart transplant recipients: results of a multicenter experience.

Authors:  Kevin P Daly; Audrey C Marshall; Julie A Vincent; Warren A Zuckerman; Timothy M Hoffman; Charles E Canter; Elizabeth D Blume; Lisa Bergersen
Journal:  J Heart Lung Transplant       Date:  2011-12-30       Impact factor: 10.247

3.  Impact of age on incidence and prevalence of moderate-to-severe cellular rejection detected by routine surveillance biopsy in pediatric heart transplantation.

Authors:  Matthew D Zinn; Michael J Wallendorf; Kathleen E Simpson; Ashley D Osborne; James K Kirklin; Charles E Canter
Journal:  J Heart Lung Transplant       Date:  2016-10-07       Impact factor: 10.247

4.  Impact of routine surveillance biopsy intensity on the diagnosis of moderate to severe cellular rejection and survival after pediatric heart transplantation.

Authors:  Matthew D Zinn; Michael J Wallendorf; Kathleen E Simpson; Ashley D Osborne; James K Kirklin; Charles E Canter
Journal:  Pediatr Transplant       Date:  2018-01-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.